key: cord-1002432-i0jgph0m
authors: Sehli, Sofia; Allali, Imane; Chahboune, Rajaa; Bakri, Youssef; Al Idrissi, Najib; Hamdi, Salsabil; Nejjari, Chakib; Amzazi, Saaïd; Ghazal, Hassan
title: Metagenomics Approaches to Investigate the Gut Microbiome of COVID-19 Patients
date: 2021-03-12
journal: Bioinform Biol Insights
DOI: 10.1177/1177932221999428
sha: 796eee309329e06b766361f65e40fba681a47d71
doc_id: 1002432
cord_uid: i0jgph0m

Over the last decade, it has become increasingly apparent that the microbiome is a central component in human well-being and illness. However, to establish innovative therapeutic methods, it is crucial to learn more about the microbiota. Thereby, the area of metagenomics and associated bioinformatics methods and tools has become considerable in the study of the human microbiome biodiversity. The application of these metagenomics approaches to studying the gut microbiome in COVID-19 patients could be one of the promising areas of research in the fight against the SARS-CoV-2 infection and disparity. Therefore, understanding how the gut microbiome is affected by or could affect the SARS-CoV-2 is very important. Herein, we present an overview of approaches and methods used in the current published studies on COVID-19 patients and the gut microbiome. The accuracy of these researches depends on the appropriate choice and the optimal use of the metagenomics bioinformatics platforms and tools. Interestingly, most studies reported that COVID-19 patients’ microbiota are enriched with opportunistic microorganisms. The choice and use of appropriate computational tools and techniques to accurately investigate the gut microbiota is therefore critical in determining the appropriate microbiome profile for diagnosis and the most reliable antiviral or preventive microbial composition.

The evolution of affordable next-generation sequencing (NGS) technologies transformed microbial research from culture-based to genome-based methods, named metagenomics. 1 This approach has been used to explore the microbial communities that interfere with the human host cells. 2 Infectious pathologies have generally relied on one disease-equivalent pathogen. 3 Nevertheless, we now realize that microbiota dysbiosis is often correlated with several distinct disease states. In many cases, a decline in the microbial diversity and growth of some particular species may contribute to harmful consequences, such as inflammation or infections. 4 Studies have given evidence of the possible participatory of the microbiome in nearly all forms of complications associated with our health, including COVID-19.

Nowadays, many researchers focus on studying the composition of the gut microbiota in relation to a disease, such as the COVID-19 caused by the SARS-CoV-2 virus. 5 A multitude of different microorganisms lives in our gut. Hence, imbalances in the composition of the intestinal microbes may induce an intestinal microbiota dysbiosis. 5 Studies in mice and humans have revealed the existing correlation between the gut microbiota dysbiosis and disease through a large scope of chronic disorders. 5 For instance, Allali et al 6 found relevant differences between the microbiota composition of healthy individuals and patients with colorectal cancer. 6 This is noteworthy that the angiotensin-converting enzyme (ACE2), known to be the host cell entry molecule of SARS-CoV-2, is found at high-level concentrations in the gastrointestinal epithelial cells and regulates intestinal inflammations. In fact, the gut microbiota is influenced by the ACE2 in an indirect way, which may indirectly induce a cardiopulmonary risk. 7 Yet, microbiome studies yield large data that require advanced computing methods, and the technologies used are constantly progressing. In addition, researchers also need to maintain vigilance that microbiome classification, data processing, and modelling is just a tiny component of the process of discovery and should be used to supplement standard in vitro and in vivo modelling approaches. Nevertheless, the use of metagenomics is changing microbiology by specifically quizzing the group 2 Bioinformatics and Biology Insights composition in an impartial course, allowing further species identification and decreasing dependency on cultural approaches 8,9 (p. 4) . The future application of these tools to enhance diagnostics and in public health environments has already been acknowledged on a large scale. 7,10 Comprehensive ongoing projects are being conducted to resolve the issues with the therapeutic employment of these techniques. 7, 11 Herein, we present and discuss bioinformatics methods and tools that are available to characterize the influence of the gut microbiome on the evolution of the COVID-19 disease or to evaluate the impact of the disease on that microbiome (Table 1) . We will also describe the studies on the human gut microbiota in relationship to the SARS-CoV-2 virus infection and discuss how these microbes would be involved in the fight against harmful microorganisms.

There are a variety of technologies accessible to research the gut microbiome. One of these technologies is gene marker analysis that uses the NGS platforms for sequencing. The common softwares used with it are QIIME2, 16 Mothur, 17 VEGAN, 18 phyloseq, 19 and DADA2. 20 The latter tools are cost-effective, and its analytical pipelines are widely accepted but lack clear functional information and can produce errors in the taxa differentiation. 21 Another widely used technology is the shotgun metagenomics, even though it is expensive and computationally demanding, it is a great approach to capture all microbial genomes within the sample. Mostly used softwares to analyse shotgun metagenomics data include IDBA-UD, 22 SPades, 23 MEGAHIT, 24 MetaPhlAn2, 25 MG-RAST, 26 and HUMAnN2. 27 Metatranscriptomics is another approach for studying the microbiome to assess gene expression level with the SOAPdenovo, 28 the commonly used software. Another approach that allows the identification and quantification of proteins within the sample is metaproteomics, but this technology does not give the protein's origin. 29 Metabolomics is a further technology used to perform profiling of the metabolites produced by the gut microbiota. 29

One of the first studies on the gut microbiome in COVID-19 patients has been carried out in Hong Kong. 12 The authors performed metagenomic analysis of 15 faecal samples extracted from patients with COVID-19. Bacterial population profiling was done using MetaPhlAn2 (v2.9), 25 which is a computational tool for profiling the composition of microbial communities from metagenomic shotgun sequencing data. 25 The obtained reads have been mapped against clade-specific markers, that are defined as coding sequences highly preserved within the genomes of the clade and that have no local similarity outside the clade with any sequence. 12 As a result, intestinal microbiome profiles correlated with disease severity and higher faecal release of SARS-CoV-2. Zuo et al 12 observed that patients with COVID-19 have substantial changes in faecal microbiome relative to the control, marked by enrichment of opportunistic microorganisms and reduction of helpful commensals, within hospitalization and at all times throughout hospitalization. 12 Depleted symbiotics and intestinal dysbiosis continued well after the elimination of SARS-CoV-2, assessed from the throat swabs, and the relief of respiratory problems. 30 The residual abundance of Coprobacillus, Clostridium hathewayi, and Clostridium ramosum was associated with the infection's severity; the abundance of Faecalibacterium prausnitzii, an antiinflammatory bacterium, was inversely correlated with the disease severity. In the middle of hospitalization, Bacteroides dorei, Bacteroides massiliensis, Bacteroides thetaiotaomicron, and Bacteroides ovatus, that reduces the expression of ACE2 in the murine intestine, are inversely linked with SARS-CoV-2 content in faecal samples of patients. 30 In another study, Zuo et al 31 (p. 19) conducted RNA metagenomic sequencing of repeated faecal viral extractions [12] Gene marker analyses (16S)

China UPARSE Increased relative abundance of Enterococcus and Rhodococcus, and decreased relative abundance of Faecalibacterium and Clostridium XlVa in COVID-19 patients [13] Metatranscriptomics China HUMAnN2 Increased transcriptional activities of Escherichia coli and Klebsiella pneumoniae, virulence factors, and antibiotic resistance genes, and decreased activities of Faecalibacterium prausnitzii in patients of COVID-19 [13] Metaproteomics China Machine-learning model

The proinflammatory cytokines were mainly found among elderly individuals compared to younger ones and that they were positively associated with the proteomic risk score [14] WGS metagenomics China BWA, MEGAHIT Microbiota of COVID-19 patients was found to contain the most known pathogens [15] Sehli et al 3 taken from 15 hospitalized patients with COVID-19. They analysed faecal microbiome diversity and the gut microbiota functionality, in accordance with faecal SARS-CoV-2 infectivity profiles 31 (p. 19) . The authors used MetaPhlAn2 (V2.9) 25 to perform taxonomic profiling of the faecal bacterial communities by mapping reads to clade-specific markers 31 (p. 19) . HUMAnN V2.0.18 27 was used to perform functional profiling of faecal bacterial communities 31 (p. 19) . Seven out of 15 patients had stool positivity for SARS-CoV-2 by viral RNA metagenomic sequencing. Furthermore, in the absence of gastrointestinal manifestations, the 7 patients displayed significantly increased coverage and density of the 3′ versus 5′ end of the coronavirus genome in their faecal viral metagenome samples 31 (p. 19) . The faecal viral metagenome of 3 cases persisted to exhibit the signature of active viral infection 31 (p. 19) . Faecal samples containing elevated SARS-CoV-2 infectiousness had greater concentrations of the bacterial species, Morganella morganii, Collinsella tanakaei, Streptococcus infantis, and Collinsella aerofaciens; while faecal samples with reduced-to-none SARS-CoV-2 infectivity had elevated abundance of bacteria that produce short-chain fatty acid, namely Bacteroides stercoris, Parabacteroides merdae, and Alistipes onderdonkii 31 (p. 19) .

In addition, Wu et al 13 examined in another study the intestinal microbiome properties of a group of COVID-19 patients throughout probiotic-assisted therapy. Wu et al 13 used UPARSE 21 to assign each operating taxonomic unit (OTU) representative sequences to a taxonomic level in the RDP database, with aid of the RDP classifier at an 80% confidence level. The authors also conducted a metatranscriptomic analysis of faecal samples using an Illumina Hiseq 4000 platform. The resulting reads were taxonomically profiled using Kraken, 13 and the relative abundance of metabolic pathways in MetaCyc 32 database was calculated using HUMAnN2. 27 ShortBRED 33 was used to quantify the abundance of antibiotic resistance genes and virulence genes against the CARD database and Virulence Factors Database. 13 Furthermore, to look for any potential agent causing pneumonia besides the coronavirus, a metagenomic study was conducted using samples of the BronchoAlveolar Large Fluid (BALF) from a patient held in the intensive care unit. The aforementioned BALF samples were used for RNA extraction and NGS sequencing using both BGI MGISEQ 2000 and Illumina MiSeq 3000 sequencers, while the metagenomic analysis was carried through the MGmapper 34 bioinformatics platform. The raw NGS reads were primarily analysed by Cutadapt (v.1.18) 35 and alignment performed using BWA (v.0.7.12-r1039) 36 against a local database. To filter reads of the hosts' genomes before aligning them against the virus database, Zhou et al 37 used a local nucleic acid database for humans and mammals. The authors used Geneious (v.11.0.3) and MEGAHIT 24 (v.1.2.9) to assemble the NGS reads. The Clone Manager Professional Suite 8 (Sci-Ed Software) was used to annotate the genomes. Results showed that more than 87% of the sequences retrieved from the BALF matched perfectly with the SARS-CoV-2 genome, 37 while the remaining ones belonged to six other viruses. Therefore, the most potentially harmful agent to be considered was the SARS-CoV-2. 37 According to the same study, a heat map of the lung microbiota composition was done by clustering the microbiota into 3 different groups (Type I, Type II, and Type III). Type I microbiota had the most pathogens, while Type II and III, respectively, contained environmental organisms and commensal species. The microbiota of patients with COVID-19 was clustered more in type I, which is considered as the most pathogenic one. 37 Another recent study analysed alterations in the mycobiome of 30 patients with COVID-19 by Zuo et al, 38 reporting that these patients compared to the controls had significant alterations in their faecal mycobiome, distinguished by the enrichment of Candida albicans and a highly heterogeneous mycobiome configuration, at the time of hospitalization. 38 With that being said, 22 of the 30 patients with COVID-19 did not significantly change from the controls during the hospitalization period. 38 Therefore, more studies are needed to conclude if the mycobiome changes and enrichment of fungal pathogens contribute to the COVID-19 progression or can be used as a predictor in it. 38 In addition to that Wang et al 39 performed some analysis on 159 Italian patients with pneumonia using a phage-display method to characterize circulating antibodies binding to 93,904 viral peptides encoded by 1,276 strains of human viruses. These researchers developed VirScan's, a tool that predicts SARS-CoV peptides and its clinical severity, an effective tool used to detect SARS-CoV-2 antibodies in the host plasma. 39 Actually, some researchers are suggesting phages as a means of therapy that could build a protective barrier to eukaryotic virus particles by an increase in phage transcytosis by epithelial cells, given that lung epithelium is also involved in transcytosis of phages. 40 Therefore, such a phenomenon may play an intriguing role in protecting those lung epithelium cells from invasion by coronaviruses. Nevertheless, further studies need to be done to conclude whether phages have the potential to at least be an adjunct treatment of the SARS-CoV-2 infection. 40 Surprisingly, none of the analysed studies measured immunity in dependence of the gut flora. However, Donati Zeppa et al, 41 stated that the various responses to the virus infection may be explained by an adaptive immune system that is not effective enough, or/and pneumonia can begin before the immune system responds. 6 The first line of defence against SARS-CoV-2 is innate immunity, the response of which, unlike the adaptive response, is activated within a few hours of the infection. 6 The natural history of the disease is determined by this first encounter between the innate immunity of the host and SARS-CoV-2 virus, and by exposure over the following 2 weeks to the virus. 41 As in another study by Yeoh et al, 42 the gut microbiota composition of COVID-19 patients was found to be consistent with the infection's severity and that many inflammatory cytokines, chemokines, and blood markers of tissue damage were found with immense concentrations in the host plasma. 42 In addition to that, the authors found that patients with COVID-19 were depleted in gut bacteria with known immunomodulatory potential, namely Faecalibacterium prausnitzii, Eubacterium rectal, and numerous bifidobacterial species. 42 However, this aspect of intestinal microbiota alterations in combination with immune dysregulation has shown that intestinal microorganisms are likely to engage in modulating host inflammatory reactions in COVID-19 infection. 42 With proof that intestinal microorganisms are associated with inflammatory diseases inside and outside the intestine, these discoveries underscore an important need to consider the particular involvement of intestinal microorganisms in human immune function and systemic inflammation. 42 From studies that performed taxonomic profiling, all COVID-19 patients (mild, moderate, critical, and severe) had an increase in pathogenic and opportunistic microorganisms, wherein severe cases had a further depletion of many bacterial species that are commensal microorganisms beneficial to the healthy and effective immunity of the host including Faecalibacterium prausnitzii that was very recurrent 12 (see Table  2 ). Twenty-three bacterial taxa were found to be significantly associated with COVID-19 disease severity, most of which (15 of 23) were from the Firmicutes phylum, among them, Erysipelotrichia and Actinobacteria classes showed positive correlation with the disease severity, while Gammaproteobacteria, Bacteroidia, and Clostridia classes showed negative correlation with disease severity. 12 Statistical studies (PERMANOVA test) on host's factors that mostly affect the gut microbiota of COVID-19 patients showed that SARS-CoV-2 infection and antibiotics treatment affect the gut microbiota, while age and gender had no significant correlation with microbiome alteration. 12

Furthermore, a metatranscriptomic analysis has been recently performed, to profile the transcriptionally active gut microbiota in patients with different types of pneumonia, which is associated with the immunity response in the lung. This study was conducted including 8 COVID-19 patients. Data from 25 patients with community-acquired pneumonia (CAP) and 20 healthy controls, have been analysed for metatranscriptome comparison. 15 Quality control comprised the trimming of adapters and the elimination of reads with low quality, using fastp software (version 0.20.0). 43 Komplexity software was used to remove low-complexity reads, Shen et al 15 used the bmtagger software to remove the hosts' reads and SortMeRNA software (version 2.1b) 44 to remove ribosomal reads. BLAST + software (version 2.9.0) 44 was used to map the subsequent reads against the NCBI Nucleotide Database. In addition, Shen et al 15 conducted a taxonomic classification using MEGAN programme (version 6.11.0). 45 Following a per-mutational multivariate analysis of variance and general key coordinate analysis, samples, and microorganisms were selected for advanced studies. Samples containing less than 5000 microbial reads have been dismissed. As a result, only samples from the BALF belonging to COVID-19 patients had SARS-CoV-2, yet some mild β-coronaviruses species were detected in the healthy and CAP patients. 15 In addition, Shen et al 15 used the BWA-MEM package (version 0.7.12) 36 to map clean metatranscriptomics reads against the COVID-19 reference genome. 15 The authors eliminated duplicated reads using Picard tool (version 2.18.22), 46 then created the mpileup file using samtools software (version 1.8) 47 and used VarScan software (version 2.3.9) 48 to define intrahost variants. For the intrahost variants in the genome of SARS-CoV-2, 84 variants were identified with a minor allele frequency (MAF) greater than 5%, and 25 variants were detected with MAF higher than 20%. Therewith, the variant number was proportional to the gene length, but only 2 out of 84 of these variants were identified in multiple patients. 15 The analysis of the lung microbiota revealed a difference between CAP, COVID-19 patients, and the healthy group, implying a dysbiosis in the lung microbiota of the unhealthy CAP and COVID-19 patients. 15

To identify one of the key underlying factors of COVID-19 disparity, in terms of the disease's severity, a very recent study suggests that the composition of the gut microbiota could partially explain the difference in susceptibility. 49 As in a set of 336 individuals, these gut microbiota features were highly correlated with proinflammatory cytokines 14 (p. 19) . The authors used UPARSE 21 to cluster sequences that have a 97% similarity into one OTU, and the RDP classifier to assign the OTUs taxonomy and to align sequences 14 (p. 19) . They additionally used the QIIME software 1.9.0 to analyse OTUs. 16 Hence, the predisposition of normal individuals to severe COVID-19 may be predicted by the gut microbiome, which brings a completely new aspect of what is currently understood about the virus 14 (p. 19) .

In another study, Tao et al 50 • The median number of intrahost virus variants was 1 to 4 in SARS-CoV-2 infected patients, which ranged between 0 and 51 in different samples.

• The distribution of variants on genes was similar to those observed in the Chinese population data.

• Very few intrahost variants were observed in the viral genome in the population as polymorphism, implying either a bottleneck or purifying selection involved in the transmission of the virus, or a consequence of the limited diversity represented in the current polymorphism data of the virus.

• Current evidence did not support the transmission of intrahost variants in a person-to-person spread; the risk should not be overlooked.

The microbiota in SARS-CoV-2 infected patients was similar to those in CAP, either dominated by the pathogens or with elevated levels of oral and upper respiratory commensal bacteria. • Kraken 13 was used to perform a taxonomy profiling of the metatranscriptomic reads.

• Then the relative abundance of metabolic pathways in MetaCyc database was calculated using HUMAnN2.

• Antibiotic resistance genes and virulence genes against the CARD database were quantified using ShortBRED.

• StrainPhlAn was used to perform a strain-level profiling.

• Bowtie2 was used to map reads against the MetaphlAn2 markers.

• A multiple sequence alignment was performed of the consensus sequences of references and samples with MUSCLE.

• RAxML was used to build a phylogenetic tree.

Alterations in Faecal • The alpha diversity of the respiratory microbiome for each patient was assessed using the Shannon diversity index (SDI).

• Diversity values were then compared between patients with and without SARS-CoV-2 infection within each group using the Wilcoxon rank sum testSpecies with differential abundance were identified within each group using DESeq2 in R at a false discovery rate (FDR) ⩽ 0.1, fold change

and P ⩽ .05.

• Vegan package in R was used to study the alpha diversity using the Shannon Wiener index.

• DESeq 2 was used to study the differential abundance of species.

VSEARCH (v2.13.0), 51 and QIIME (v1.9.1) 16 to analyse data for microbial diversity. Unfortunately, the aforementioned tools do not give clear functional information and may give errors in taxa differentiation. Alpha-diversity analysis demonstrated that the gut microbiota composition was less diverse in COVID-19 patients in contrast with both flu patients and control cases. 50 Assessed by weighted UniFrac, 52 the genus level in each group revealed that the abundance and composition of faecal bacteria in COVID-19 patients varied from those in both control cases and seasonal influenza patients. 50 The increased abundance of Streptococcus in COVID-19 patients was indicative of the risk of infection by opportunistic pathogenic bacteria in this group. However, the approach used in this study was not enough to capture all microbial genomes within samples and thus not reaching the species level. 50

Pithily, we are on the brink of a quickly evolving research field that holds an enormous opportunity to clarify and describe microbial interactions on the human interrelatedness. Early in the COVID-19 pandemic, researchers smartly pointed to the microbiome as a key element in understanding the etiology, infection, and transmissibility processes of the emerging SARS-CoV-2 virus. Three out of 5 studies reported that there was (1) a significant enrichment of opportunistic microorganisms such as Clostridium hathewayi, Actinomyces viscosus, Bacteroides nordii; 29 (2) reduction of helpful commensals in COVID-19 patients, and (3) an interesting decrease of Faecalibacterium prausnitzii in patients with COVID-19. [1] [2] [3] Faecalibacterium prausnitzii plays an important role in promoting gut health. 4 The aforementioned species may be a useful potential biomarker in diagnostics and prognostics for certain diseases, such as Crohn's disease, and ulcerative colitis. 4 Faecalibacterium prausnitzii has frequently been identified as one of the major butyrate contributors in the gut. 4 Butyrate plays a significant part in the physiology of the intestines and in the well-being of the host. 4 Butyrate can minimize inflammation in the intestinal mucosa by inhibiting the activation of NF-κB transcription factor, up-regulating PPARγ, and inhibiting interferon gamma (IFN-γ). 4 Moreover, anti-inflammatory properties have been linked to this species due to its capacity to cause a tolerogenic cytokine profile (with quite low secretion of proinflammatory cytokines such as interleukin [IL]-12 and IFN-γ) and enhanced secretion of anti-inflammatory cytokines IL-10. 4 We reported these few studies to shed further light on this promising route for new diagnostics and therapeutic strategies, yet we acknowledge that it is too early to make strong conclusions. It is noteworthy that most available metagenomics tools do not reach the optimal level of accuracy. After all, most taxonomic classifiers are also encumbered by a large number of false positives at the poor abundance that needs to be discussed. Further than this, significant advances and innovation will be required in so many other ways, namely in managing experimental contamination sources and bias and in managing the rapid growth of reference databases, to establish worldchanging improvements in metagenomics classification towards microbial identification and classification (Table 3) . Actually, our current scientific information and understanding of the gut microbiota and COVID-19 relationship is less than precise but continues to evolve fast. Thus, understanding how to choose the computational tools and strategies to analyse efficiently the gut microbiota is one important thing to decipher the most pertinent microbiome profile for diagnostics and the precise antiviral or preventive microbial composition.

Metagenomics: genomic analysis of microbial communities

Progress of analytical tools and techniques for human gut microbiome research

The modern doctrine of bacteriology, or the germ theory of disease

Role of the microbiota in immunity and inflammation

The human intestinal microbiome in health and disease

Gut microbiome of Moroccan colorectal cancer patients

Laboratory validation of a clinical metagenomic sequencing assay for pathogen detection in cerebrospinal fluid

Bayesian community-wide cultureindependent microbial source tracking

A culture-independent sequence-based metagenomics approach to the investigation of an outbreak of Shiga-toxigenic Escherichia coli O104:H4

Metagenomics for pathogen detection in public health

Clinical metagenomics

Alterations in gut microbiota of patients with COVID-19 during time of hospitalization

The volatile and heterogenous gut microbiota shifts of COVID-19 patients over the course of a probiotics-assisted therapy

Gut microbiota may underlie the predisposition of healthy individuals to COVID-19

Genomic diversity of severe acute respiratory syndrome-coronavirus 2 in patients with coronavirus disease 2019

QIIME allows analysis of highthroughput community sequencing data

Introducing Mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities

phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data

DADA2: high-resolution sample inference from Illumina amplicon data

UPARSE: highly accurate OTU sequences from microbial amplicon reads

IDBA-UD: a de novo assembler for single-cell and metagenomic sequencing data with highly uneven depth

SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing

MEGAHIT: an ultra-fast single-node solution for large and complex metagenomics assembly via succinct de Bruijn graph

Metagenomic microbial community profiling using unique clade-specific marker genes

The metagenomics RAST server -a public resource for the automatic phylogenetic and functional analysis of metagenomes

Species-level functional profiling of metagenomes and metatranscriptomes

SOAPdenovo2: an empirically improved memoryefficient short-read de novo assembler

Tools for analysis of the microbiome

Composition, variability, and temporal stability of the intestinal microbiota of the elderly

Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19

The MetaCyc database of metabolic pathways and enzymes

High-specificity targeted functional profiling in microbial communities with ShortBRED

MGmapper: reference based mapping and taxonomy annotation of metagenomics sequence reads

Cutadapt removes adapter sequences from high-throughput sequencing reads

Fast and accurate short read alignment with Burrows-Wheeler transform

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Alterations in fecal fungal microbiome of patients with COVID-19 during time of hospitalization until discharge

Serological responses to human virome define clinical outcomes of Italian patients infected with SARS-CoV-2

Phages in the fight against COVID-19

Gut microbiota status in COVID-19: an unrecognized player

Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19

fastp: an ultra-fast all-in-one FASTQ preprocessor

BLAST+: architecture and applications

MEGAN analysis of metagenomic data

The GATK joint genotyping workflow is appropriate for calling variants in RNA-seq experiments

The sequence alignment/map format and SAMtools

VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing

Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18 and SARS-CoV-2-specific IgA

VSEARCH: a versatile open source tool for metagenomics

UniFrac: a new phylogenetic method for comparing microbial communities

Metatranscriptomic characterization of coronavirus disease 2019 identified a host transcriptional classifier associated with immune signaling

Hassan Ghazal https://orcid.org/0000-0002-0638-2180